Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Umbilical Cord Blood for Ischemic Stroke
NCT02397018Phase 1Completed
- Sponsor
- Joanne Kurtzberg
- Start
- May 2015
- Primary completion
- Feb 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic human umbilical cord blood in ischemic stroke, sponsored by Joanne Kurtzberg. Primary endpoints: Adverse Events at 12 months and Graft Versus Host Disease at 100 days. Started May 2015; status: completed.
02
Drugs
allogeneic human umbilical cord blood
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02397018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397018.